Vertex Pharmaceuticals Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vertex Pharmaceuticals Inc's ROA in the second quarter of 2026?
Vertex Pharmaceuticals Inc achieved a return on average assets (ROA) of 16.88 % in its second quarter of 2026, this is above VRTX's average return on assets of 2.57%.
Vertex Pharmaceuticals Incs assets during the 12 months ending in the second quarter of 2026 are valued at $26 billion

ROA fell compared to the first quarter of 2026, despite the net income growth of 6.63% from the first quarter of 2026.

However, within the Healthcare sector 60 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 288, from total ROA ranking in the first quarter of 2026 at 357.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	49.03 %	49.34 %	86.59 %	79.61 %	41.58 %
Y / Y Net Income Change	6.48 %	59.59 %	30.46 %	3.59 %	-
Net Income (TTM) in million	4,405	4,338	3,953	3,675	3,638
Return On Assets (TTM)	16.88 %	18.19 %	18.25 %	19.67 %	22.83 %
VRTX's Total Ranking	# 288	# 357	# 335	# 319	# 3029
Total Assets (TTM) in million	27,423	26,484	25,643	24,862	18,401
Seq. Total Assets Change	3.55 %	3.28 %	3.14 %	35.12 %	3.75 %
Seq. Net Income Change	6.63 %	-13.41 %	9.99 %	4.84 %	59.82 %

VRTX's 5 Years Annual ROA >> Back to VRTX Management Effectiveness >> Compare VRTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 31
Sector	# 61
Overall	# 290

Return On Assets Statistics
High	Average	Low
43.58 %	2.57 %	-43.51 %
(Dec 31 2018)		(Mar 31 2011)

Financial Statements
Vertex Pharmaceuticals Inc's Assets	$ 27,423 million	VRTX's Balance sheet
Vertex Pharmaceuticals Inc's Income	$ 1,100 million	Quarterly VRTX's Income Statement
VRTX's Income by Division		See VRTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	66.36 %	-8.62 %	24.57 %	36.07 %	15.4 %
Total Assets in million	31,355	18,848	20,627	16,558	12,169
Y / Y Net Income Change	-	-	8.96 %	41.84 %	-13.63 %
Net Income in million	3,953	-536	3,620	3,322	2,342
Annual Return On Assets	12.61 %	-2.84 %	17.55 %	20.06 %	19.25 %

VRTX's 5 Years Annual ROA >> Back to VRTX Management Effectiveness >> Compare VRTX ROA to its Competitors

Comment on VRTX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 12.61 % compared to prior year, due to annual net income growth of % to $3,953.20 million, while value of Vertex Pharmaceuticals Inc's overall assets grew just by 66.36 % to $31,355.30 million, compared to $31,355.30 a year before.

More Return On Assets Ratios
VRTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VRTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VRTX's Competitors
Subscribers only: Roa for Vertex Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for VRTX's Customers

You may also want to know
VRTX's Roi	VRTX's Inventory Turnover Ratio	VRTX's Growth Rates	VRTX's Dividend Comparisons
	VRTX's Profitability Ratios	VRTX's Asset Turnover Ratio	VRTX's Dividend Growth
VRTX's Roe	VRTX's Valuation Ratios	VRTX's Financial Strength Ratios	VRTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %

Date modified: 2026-09-02T20:09:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.